The World's Best Long-Term Hope for Ending AIDS

The HVTN uses an integrated approach to HIV prevention to advance the fields of vaccinology, social and behavioral sciences, statistics, and immunology, as well as COVID-19 and tuberculosis (TB) vaccines.  

70+

Study Sites

Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.

100+

Clinical Trials

For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.

74

Scholar Awards

We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.

HVTN Mission

Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.

What We Do

Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. 

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.

It Takes a Village

The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.

Recent HVTN News & Announcements

Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future

Harmonized approach and vast database of trial participants could bolster future research well beyond SARS-CoV-2. 

Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued

A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board.

Read the Latest Community Compass Issue

In this issue, we acknowledge the recent passing of our dear colleague and long-time HIV activist Giulio Corbelli, a recent announcement of Dr. Anthony Fauci stepping down from his role as Director of NIAID, a recent statement from experts regarding the importance of including people living with HIV in TB research, along with many other HVTN updates.

News on HVTN

Read More
Year in Pictures: 2022 A look back at the year through compelling images December 12, 2022
Could a 100-year-old TB vaccine help scientists find a better one? Harmless vaccine BCG is made of living bacteria; in tests might serve as a proxy for deadly tuberculosis December 12, 2022
Dr. Larry Corey receives Alexander Fleming Award Virologist honored by peers for his lifetime achievements against infectious diseases October 21, 2022
Fauci visits Fred Hutch, discusses pandemics, vaccines and scientific misinformation NIAID director’s determined spirit recognized with honorary Hutch Award August 10, 2022

RAMP Scholar Grant

The Research and Mentorship Program (RAMP) provides structured mentorship and project funding to African American/Black and Hispanic/Latinx medical students in areas of basic, clinical behavioral, laboratory and social sciences.